Want to see IN:ALEMBICLTD full AI Analyst Report?

Alembic Limited (ALEMBICLTD) Price & Analysis

3 Followers

ALEMBICLTD Stock Chart & Stats

₹103.40

-₹1.48(-1.12%)

At close: Jan 09 4:00 PM EST

₹103.40

-₹1.48(-1.12%)

Day’s Range― - ―

52-Week Range₹70.64 - ₹117.91

Previous CloseN/A

Volume165.88K

Average Volume (3M)147.70K

Market Cap

₹26.89B

Enterprise Value₹17.32K

Total Cash (Recent Filing)₹980.38M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)8.5

Beta1.42

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.26%

Share Statistics

EPS (TTM)12.48

Shares Outstanding256,781,830

10 Day Avg. Volume47,709

30 Day Avg. Volume147,697

Financial Highlights & Ratios

PEG Ratio2.67

Price to Book (P/B)0.74

Price to Sales (P/S)7.59

P/FCF Ratio17.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Steady Revenue GrowthThe multi-year increase in revenue indicates sustained expansion of the pharmaceutical business rather than reliance on a single reporting period. Continued growth across branded formulations, generics, and APIs can support reinvestment and strengthen the company’s operating base over the next several quarters.

Very Low LeverageMinimal debt materially reduces solvency and refinancing pressure, giving Alembic greater flexibility through changing business conditions. A conservatively financed balance sheet also preserves capacity to fund products, facilities, and working capital without imposing a heavy recurring interest burden.

Improving Cash GenerationThe sharp improvement in operating and free cash flow provides stronger internal funding for investment, debt avoidance, and shareholder returns. If maintained, this recent conversion improvement would make growth more self-financed and reduce dependence on accounting earnings alone.

Bears Say

Operating Profitability DeclineThe deterioration in EBITDA and EBIT shows that reported revenue growth did not translate into stronger operating profitability in 2026. Persistently weaker operating earnings could reduce funds available for development and make future performance more dependent on non-operating items.

Volatile Cash ConversionDespite the strong 2026 recovery, the prior pattern of negative operating and free cash flow demonstrates uneven conversion over the business cycle. Such variability can complicate investment planning and weaken confidence that reported profits consistently translate into available cash.

Earnings Quality RiskNet income that exceeds revenue creates a potentially unstable earnings base because reported profits may include substantial non-operating or one-off contributions. This makes underlying profitability harder to assess and raises the risk that earnings will not remain representative of recurring pharmaceutical operations.

Alembic Limited News

Alembic Limited Opens Special Window for Share Transfer Re-lodgement

Alembic Limited ( ($IN:ALEMBICLTD) ) has issued an announcement. Alembic Limited has announced a special window for the...

11M ago

Alembic Limited Updates Registrar Contact Details

Alembic Limited ( ($IN:ALEMBICLTD) ) has issued an announcement. Alembic Limited announced a change in the email and...

1y ago

ALEMBICLTD FAQ

What was Alembic Limited’s price range in the past 12 months?

Alembic Limited lowest stock price was ₹70.64 and its highest was ₹117.91 in the past 12 months.

What is Alembic Limited’s market cap?

Alembic Limited’s market cap is ₹26.89B.

When is Alembic Limited’s upcoming earnings report date?

Alembic Limited’s upcoming earnings report date is Nov 06, 2026 which is in 42 days.

How were Alembic Limited’s earnings last quarter?

Alembic Limited released its earnings results on Aug 11, 2026. The company reported ₹2.527 earnings per share for the quarter.

Is Alembic Limited overvalued?

According to Wall Street analysts Alembic Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Limited pay dividends?

Alembic Limited pays a Annually dividend of ₹2.4 which represents an annual dividend yield of 2.26%. See more information on Alembic Limited dividends here

What is Alembic Limited’s EPS estimate?

Alembic Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alembic Limited have?

Alembic Limited has 256,781,830 shares outstanding.

What happened to Alembic Limited’s price movement after its last earnings report?

Alembic Limited reported an EPS of ₹2.527 in its last earnings report. Following the earnings report the stock price went up 2.432%.

Which hedge fund is a major shareholder of Alembic Limited?

Currently, no hedge funds are holding shares in IN:ALEMBICLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Limited

Alembic Limited primarily manufactures and globally distributes active pharmaceutical ingredients (APIs) developed through both fermentation and chemical synthesis. The company operates across two distinct divisions: API and Real Estate. In its real estate ventures, Alembic undertakes the construction of residential and commercial properties, offers project management and marketing consultancy services, and leases commercial spaces. Furthermore, it operates its own power generation facilities, including co-generation plants with a total capacity of 11 MW and wind power plants contributing 5 MW. Founded in 1907 and headquartered in Vadodara, India, Alembic Limited is a subsidiary of Nirayu Limited.